OCX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	15 346.00
Gjennomsnittsvolum	59 472.00
Markedsverdi	35.55M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $-0.820 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.790
ATR14	$0.0410 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Broadwood Partners, L.p.	Buy	2 420 000	Common Stock, no par value
2024-04-11	Broadwood Partners, L.p.	Buy	0	Common Stock, no par value
2024-04-15	Broadwood Partners, L.p.	Sell	0	Series A Convertible Preferred Stock
2024-04-11	Riggs Josh	Buy	3 390	Common Stock, no par value
2024-04-11	Arno Andrew	Buy	33 898	Common Stock, no par value

INSIDER POWER
37.39
Last 97 transactions
Buy: 36 875 696 \| Sell: 16 930 326

OncoCyte Corp Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

OncoCyte Corp Korrelasjon - Valuta/Råvare

-0.14
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.44
( neutral )

-0.21
( neutral )

OncoCyte Corp Økonomi

Annual	2023
Omsetning:	$1.50M
Bruttogevinst:	$501 000 (33.33 %)
EPS:	$-3.63

FY	2023
Omsetning:	$1.50M
Bruttogevinst:	$501 000 (33.33 %)
EPS:	$-3.63

FY	2022
Omsetning:	$958 000
Bruttogevinst:	$-18 000.00 (-1.88 %)
EPS:	$-13.26

FY	2021
Omsetning:	$7.73M
Bruttogevinst:	$188 000 (2.43 %)
EPS:	$-0.720

Financial Reports:

No articles found.

OncoCyte Corp

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Sanntidsoppdatering for OncoCyte Corp [OCX]

Upcoming Earnings Alert